Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
We first bought Moderna (MRNA) in April 2025, when investors were focused on the collapse in COVID vaccine revenue and its R&D cash burn. At our initial...
— Evan Tindell
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Moderna, Inc.
Moderna’s recent recovery is welcome, but it also needs perspective. Even after the...
Moderna, a popular short position, was the main driver of sector performance. The shares rose...
Moderna, Inc. is a biotechnology company developing mRNA-based vaccines and therapeutics across infectious disease and oncology. Shares rose sharply...
More institutional theses from Bireme Capital
YouGov (YOU) is a pioneer of online polling. Founded in the...
M-Up Holdings (3661) operates Fanplus, a leading Japanese platform for musicians’ fan clubs. Fans pay monthly...
We first invested in Disney (DIS) in January 2024, when pessimism about the company was widespread: on the popular All-In podcast’s year-end awards show, two of the four hosts named Disney the biggest business loser of 2023. At roughly $92...